We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan.
- Authors
KUWAYAMA, H.; ASAKA, M.; SUGIYAMA, T.; FUKUDA, Y.; AOYAMA, N.; HIRAI, Y.; FUJIOKA, T.
- Abstract
Background Large-scale studies of rabeprazole-based Helicobacter pylori eradication therapy have not been reported in Japan. Aims To evaluate H. pylori eradication by rabeprazole-based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages. Methods From 35 centres 479 H. pylori-positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days); Group 2 (10 mg, 750 mg, 400 mg); Group 3 (20 mg, 750 mg, 200 mg) and Group 4 (20 mg, 750 mg, 400 mg). Results Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1–4, respectively. The eradication rate was 95% (360 of 379) for clarithromycin-susceptible strains, and 50% (30 of 60) for clarithromycin-resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively. Conclusions Rabeprazole-based therapies achieved 50% eradication of clarithromycin-resistant H. pylori, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first-line proton pump inhibitor-based triple therapy for H. pylori.
- Subjects
JAPAN; TREATMENT of helicobacter pylori infections; HELICOBACTER pylori; ANTIBIOTICS; PROTON pump inhibitors
- Publication
Alimentary Pharmacology & Therapeutics, 2007, Vol 25, Issue 9, p1105
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2007.03298.x